The video interview of Dr Judy Mikovits has gone viral.

After I have seen this video namely Fact-checking Judy Mikovits, the controversial virologist attacking Anthony Fauci in a viral conspiracy video by Matin Enserink, Jon Cohen, May 8 2020, I doubted its accuracy. If it is true, Dr Fauci is a multi-billionaire.

So, I Googled “Patents by Anthony S. Fauci” and I was shocked to see the following:   

Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

• Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin

Patent number: 9896509

Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Type: Grant

Filed: August 3, 2016

Date of Patent: February 20, 2018

Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services

Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN

Publication number: 20160333097

Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Type: Application

Filed: August 3, 2016

Publication date: November 17, 2016

Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv

Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin

Patent number: 9441041

Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Type: Grant

Filed: September 21, 2015

Date of Patent: September 13, 2016

Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services

Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN

Publication number: 20160075786

Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Type: Application

Filed: September 21, 2015

Publication date: March 17, 2016

Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv

Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION

Publication number: 20090285815

Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.

Type: Application

Filed: March 21, 2008

Publication date: November 19, 2009

Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

• Fusion protein including of CD4

Patent number: 7368114

Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

Type: Grant

Filed: October 24, 2002

Date of Patent: May 6, 2008

Assignee: The United States of America as represented by the Department of Health and Human Services

Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

• HIV related peptides

Patent number: 6911527

Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

Type: Grant

Filed: January 7, 2000

Date of Patent: June 28, 2005

Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services

Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci

• Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4

Publication number: 20040265306

Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.

Type: Application

Filed: July 27, 2004

Publication date: December 30, 2004

Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

Publication number: 20030180254

Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

Type: Application

Filed: January 23, 2003

Publication date: September 25, 2003

Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services

Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

Patent number: 6548055

Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

Type: Grant

Filed: August 9, 2000

Date of Patent: April 15, 2003

Assignee: The United States of America as represented by the Department of Health and Human Services

Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

Patent number: 6190656

Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

Type: Grant

Filed: September 2, 1997

Date of Patent: February 20, 2001

Assignee: The United States of America as represented by the Department of Health and Human Services

Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

Patent number: 5696079

Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

Type: Grant

Filed: May 26, 1995

Date of Patent: December 9, 1997

Assignee: The United States of America as represented by the Department of Health and Human Services

Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci